Influenza in High-Risk Patients: Aching for Optimal Treatment

Activity Overview

In this activity, a panel of experts discusses therapeutic options for influenza and reasons why influenza treatment is commonly overlooked even in high-risk patients. Challenges in diagnosing and treating influenza in the era of COVID-19 are highlighted. A high-risk experienced influenza patient shares her experiences with diagnosis and treatment and how influenza affected her quality of life.

Credit Expired
0.50 CE Credit(s)
Expires: October 17, 2022

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Faculty

Ison 300x400

Michael G. Ison, MD, MS

Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Christopher J. Coyne, MD, MPH

Director, Clinical Research Department of Emergency Medicine
University of California San Diego
San Diego, CA

Zimmerman 300x400

Richard K. Zimmerman, MD, MPH, MS

Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources